• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

膀胱肿瘤的DNA恶性分级及其临床意义。

DNA-malignancy-grading of bladder tumor and its clinical significance.

作者信息

Wang X Z, Ma Y J, Zheng J F, Qin H Y

机构信息

Department of Urology, Changhai Hospital, Second Military Medical University.

出版信息

Chin Med J (Engl). 1992 Oct;105(10):856-9.

PMID:1291205
Abstract

The DNA-Malignancy-Grade(DNA-MG) of paraffin-embedded tumor specimens from 38 patients with bladder tumor was determined by image cytometry. A good correlation was found of DNA-MG with clinical staging and histopathological grading. The DNA-MG of T1 and G1 bladder tumor was less than 3.00, while that of T3-4 and G3 bladder tumor was greater than 3.00. The 5-year survival of patients with DNA-MG < 3.00 and > 3.00 was 100% and 36.9%, respectively. The data indicate that DNA-MG plays an important role in the assessment of the prognosis and the planning of treatment.

摘要

采用图像细胞术测定了38例膀胱肿瘤患者石蜡包埋肿瘤标本的DNA恶性度分级(DNA-MG)。发现DNA-MG与临床分期和组织病理学分级具有良好的相关性。T1期和G1级膀胱肿瘤的DNA-MG小于3.00,而T3-4期和G3级膀胱肿瘤的DNA-MG大于3.00。DNA-MG<3.00和>3.00的患者5年生存率分别为100%和36.9%。数据表明,DNA-MG在预后评估和治疗方案制定中起重要作用。

相似文献

1
DNA-malignancy-grading of bladder tumor and its clinical significance.膀胱肿瘤的DNA恶性分级及其临床意义。
Chin Med J (Engl). 1992 Oct;105(10):856-9.
2
[Clinical significance of the stereological estimation of mean nuclear volume in human bladder carcinoma--relation to tumor grade, stage and prognosis].[人体膀胱癌平均核体积的体视学估计的临床意义——与肿瘤分级、分期及预后的关系]
Hinyokika Kiyo. 1992 Jan;38(1):25-9.
3
The value of DNA cytometry in transitional cell carcinoma of the urinary bladder.
Gen Diagn Pathol. 1997 Dec;143(4):231-6.
4
Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.根据日本登记膀胱癌患者的数据得出的Ta、T1期非肌层浸润性膀胱癌肿瘤复发的临床结果:日本泌尿外科学会1999 - 2001年报告
Int J Urol. 2009 Mar;16(3):279-86. doi: 10.1111/j.1442-2042.2008.02235.x. Epub 2009 Jan 20.
5
Prognostic value of static cytometry in transitional cell carcinoma of the bladder: recurrence rate and survival in a group of patients at 10 years follow-up.静态细胞计数法对膀胱移行细胞癌的预后价值:一组患者10年随访的复发率和生存率
Oncol Rep. 2006 Jan;15(1):213-9.
6
[A clinicopathological study on patients with bladder cancer treated with cystectomy].[膀胱癌患者膀胱切除术的临床病理研究]
Hinyokika Kiyo. 1990 Oct;36(10):1149-54.
7
[Treatment of 300 patients with bladder cancer].[300例膀胱癌患者的治疗]
Hinyokika Kiyo. 1991 Oct;37(10):1235-41.
8
Prognostic factors for survival in patients with transitional cell carcinoma of the bladder: evaluation by histopathologic grade, pathologic stage and flow-cytometric analysis.膀胱移行细胞癌患者生存的预后因素:通过组织病理学分级、病理分期和流式细胞术分析进行评估。
Eur Urol. 1996;29(2):193-8.
9
[Prognostic significance of DNA content in transitional cell carcinoma of the urinary bladder].[膀胱移行细胞癌中DNA含量的预后意义]
Zhonghua Zhong Liu Za Zhi. 1992 Jan;14(1):24-6.
10
[The DNA content of bladder carcinoma in relation to pathologic grading, staging and prognosis: a flow cytometric study].[膀胱癌的DNA含量与病理分级、分期及预后的关系:一项流式细胞术研究]
Zhonghua Wai Ke Za Zhi. 1989 Nov;27(11):650-3, 700.